Research programme: calcium-sensing receptor antagonists - NPS Pharmaceuticals/GlaxoSmithKline
Alternative Names: Calcilytics - NPS Pharmaceuticals/GlaxoSmithKline; NPS 2143; NPS 89636; SB-262470; SKF 45675Latest Information Update: 10 Aug 2011
At a glance
- Originator NPS Pharmaceuticals
- Class Naphthalenes; Pyrimidinones; Small molecules
- Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Postmenopausal osteoporosis